A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer - Carlson, Robert W.; O’Neill, Anne; Vidaurre, Tatiana; Gomez, Henry L.; Badve, Sunil S.; Sledge, George W. (Breast cancer research and treatment, 2012)
Keywords: Adult; Aged; Aged, 80 and over; Antineoplastic agents; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - metabolism; Breast Neoplasms - mortality; Breast Neoplasms - pathology; Cancer; Cancer research; Cancer therapies; Care and treatment; Clinical Trial; Clinical trials; Diarrhea; Drug therapy; Estradiol - administration & dosage; Estradiol - analogs & derivatives; Estrogen; Female; Gefitinib; Gynecology. Andrology. Obstetrics; Hormones; Humans; Mammary gland diseases; Medical sciences; Medicine; Medicine & Public Health; Metastasis; Middle Aged; Neoplasm Metastasis; Nitriles - administration & dosage; Oncology; Pharmacology. Drug treatments; Postmenopausal women; Quinazolines - administration & dosage; Receptors, Estrogen - metabolism; Receptors, Progesterone - metabolism; Survival Analysis; Treatment Outcome; Triazoles - administration & dosage; Tumors; Metastatic breast cancer; Gefitinib; Anastrozole; Randomized phase II; Fulvestrant; Antineoplastic agent; Estrogen receptor; Breast disease; Azole derivatives; Quinazoline derivatives; Menopause; Antiestrogen; Antihormone; Estrogen synthase; Metastasis; EGFR tyrosine kinase inhibitor; Randomization; Phase II trial; Postmenopause; Adult; Clinical trial; Female; Advanced stage; Antagonist; Woman; Non steroid compound; Protein-tyrosine kinase; Human; Drug; Drug combination; Aromatase inhibitor; Enzyme; Tyrosine kinase inhibitor; Transferases; Enzyme inhibitor; Breast cancer; Malignant tumor; Mammary gland diseases; Chemotherapy; Treatment; Triazole derivatives; Cancer; Hormonal receptor